| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for I7G from our risk checks.
Ipsen S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €108.80 |
| 52 Week High | €129.70 |
| 52 Week Low | €100.30 |
| Beta | 0.60 |
| 11 Month Change | 6.15% |
| 3 Month Change | -13.17% |
| 1 Year Change | -12.26% |
| 33 Year Change | 35.76% |
| 5 Year Change | 17.94% |
| Change since IPO | 394.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| I7G | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -0.3% | -1.8% | -2.5% |
| 1Y | -12.3% | -15.4% | 3.4% |
Return vs Industry: I7G exceeded the German Pharmaceuticals industry which returned -16.6% over the past year.
Return vs Market: I7G underperformed the German Market which returned 3.9% over the past year.
Price Volatility
| I7G volatility | |
|---|---|
| I7G Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: I7G has not had significant price volatility in the past 3 months.
Volatility Over Time: I7G's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1929 | 5,325 | David Loew | www.ipsen.com |
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.
Ipsen S.A. Fundamentals Summary
| I7G fundamental statistics | |
|---|---|
| Market cap | €8.82b |
| Earnings (TTM) | €663.90m |
| Revenue (TTM) | €3.44b |
13.3x
P/E Ratio2.6x
P/S RatioIs I7G overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| I7G income statement (TTM) | |
|---|---|
| Revenue | €3.44b |
| Cost of Revenue | €618.00m |
| Gross Profit | €2.82b |
| Other Expenses | €2.15b |
| Earnings | €663.90m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.04 |
| Gross Margin | 82.01% |
| Net Profit Margin | 19.33% |
| Debt/Equity Ratio | 9.6% |
How did I7G perform over the long term?
See historical performance and comparison